Free Trial

3 Stocks Getting Rare Double Upgrades From Analysts

Double Upgrade Issued stock metrics - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.

Key Points

  • Advance Auto Parts is gaining analyst favor as its turnaround plan shows results, offering upside versus overvalued peers like AZO and ORLY.
  • BioLineRx received a Strong Buy upgrade after transferring APHEXDA rights to Ayrmid Bio, allowing focus on its oncology pipeline.
  • Anheuser-Busch beat EPS expectations and is thriving on brand strength and non-alcoholic beer growth despite broader sector weakness.
  • Five stocks to consider instead of Anheuser-Busch InBev SA/NV.

Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts’ expectations. However, that can become an opportunity for nimble investors with some cash on the sidelines.

With earnings season wrapping up, some analysts have discovered they were too bearish on a company. That causes them to upgrade the stock, which usually comes with a higher price target.

But some analysts don’t stop with one upgrade. They sometimes upgrade a stock by two rating levels, though not often.

If one upgrade is good, two must be better. That’s not necessarily true, but it does signal that analysts are trying to catch up to a stock. That’s the case with these three stocks that have received a double upgrade from analysts since their most recent earnings reports.

Advance Auto Parts' Turnaround Is Taking Shape

Advance Auto Parts Stock Forecast Today

12-Month Stock Price Forecast:
$46.25
-0.04% Downside
Reduce
Based on 22 Analyst Ratings
Current Price$46.26
High Forecast$55.00
Average Forecast$46.25
Low Forecast$34.00
Advance Auto Parts Stock Forecast Details

Advance Auto Parts Inc. NYSE: AAP has been a laggard compared to sector leaders like AutoZone Inc. NYSE: AZO and O’Reilly Auto Parts Inc. NASDAQ: ORLY. However, analysts appear to be warming up to the idea that at a time when high interest rates may suppress new car purchases, there’s room for many companies at this table.

That was the sentiment of Redburn Partners, which raised AAP stock from Sell to Neutral. It also raised its price target from $28 to $45.

The reasons have to do with strengthening fundamentals. Advance Auto Parts is in the middle of a multi-year turnaround plan that is moving beyond cost-cutting and raising optimism of an increase in gross margins as it finds efficiency in its supply chain and with private label brands.

Adding interest for investors is that AZO and ORLY are trading at valuations that make them expensive compared to their history. That could make AAP the asymmetric play for investors looking to catch a stock that may have strong upside if institutions follow the analysts’ lead.

BioLineRx Is Moving Closer to Another Breakthrough

BioLineRx Stock Forecast Today

12-Month Stock Price Forecast:
$26.00
476.50% Upside
Strong Buy
Based on 2 Analyst Ratings
Current Price$4.51
High Forecast$26.00
Average Forecast$26.00
Low Forecast$26.00
BioLineRx Stock Forecast Details

BioLineRx Ltd. NASDAQ: BLRX is a commercial stage biopharmaceutical company that develops and commercializes therapeutics for oncology and rare diseases. The company’s mulitiple myeloma drug, APHEXDA, was approved in late 2023. That marked a three-year high for BLRX stock which has fallen back to near penny stock levels since.

However, Jones Trading recently upgraded the stock from a Hold to a Strong Buy. There could be a couple of reasons for the bullish sentiment.

First, the company completed the transfer of its U.S. commercial rights to APHEXDA to Ayrmid Bio in the fourth quarter of 2024. This allows BioLineRx to focus on its stage oncology pipeline and its lead candidate, motixafortid, for pancreatic cancer.

Second, BioLine's equity stake in the partnership with Ayrmid de-risks the company from the cash burn associated with commercial production of APHEXDA while allowing it to receive milestone payments and royalties.

BUD Continues to Be the Best Option in a Weak Sector

Anheuser-Busch InBev SA/NV Stock Forecast Today

12-Month Stock Price Forecast:
$71.50
4.60% Upside
Buy
Based on 10 Analyst Ratings
Current Price$68.36
High Forecast$88.00
Average Forecast$71.50
Low Forecast$55.00
Anheuser-Busch InBev SA/NV Stock Forecast Details

Consumer staples stocks have been under pressure as consumers absorb the double whammy of sticky inflation and higher interest rates. Normally, stocks such as Anheuser-Busch InBev Inc. NYSE: BUD perform well in these times due to their defensive nature.

But this isn’t an ordinary time. Alcohol consumption is under pressure due to the GLP-1 movement. Also, many U.S. consumers are rethinking their relationship with alcohol. A 2025 study by NCSolutions cites 49% of Americans plan to drink less in 2025. That’s up from 41% in 2024. The reasons are both financial and an increased focus on wellness associated with sobriety.

However, the recent earnings from Anheuser-Busch is a reminder of a timeless truth. It pays to have best-in-class brands. In addition to having the number one and two volume share gainers, as well as a group of beers that capitalized on the premiumization trend, the company also has a growing non-alcoholic beer category that is helping boost sales.

That was on display in the company’s first quarter 2025 earnings report. Revenue missed estimates slightly on falling volume, but the company beat earnings per share (EPS) estimates by more than 10%. Since the earnings report BNP Paribas raised its rating on BUD stock from a Hold to a Strong Buy.

Should You Invest $1,000 in Anheuser-Busch InBev SA/NV Right Now?

Before you consider Anheuser-Busch InBev SA/NV, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anheuser-Busch InBev SA/NV wasn't on the list.

While Anheuser-Busch InBev SA/NV currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Chris Markoch
About The Editor

Chris Markoch

Editor & Contributing Author

Value Investing, Retirement, Dividend Stocks, Individual Investing

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRankâ„¢Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Advance Auto Parts (AAP)
3.5153 of 5 stars
$46.420.3%2.15%-7.91Reduce$46.25
BioLineRx (BLRX)
2.8716 of 5 stars
$4.430.7%N/A-0.50Strong Buy$26.00
Anheuser-Busch InBev SA/NV (BUD)
1.9558 of 5 stars
$68.48-0.9%1.24%19.85Buy$71.50
AutoZone (AZO)
4.6975 of 5 stars
$3,606.822.4%N/A24.41Buy$4,072.24
O'Reilly Automotive (ORLY)
4.0548 of 5 stars
$89.161.1%N/A32.77Buy$94.30
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

NVIDIA: Another 200% Growth Ahead? (PLUS 2 Companies Riding Along)
3 Rising Stocks You’ll Want on Your Watchlist
Trillions in Defense Spending—3 Disruptive Stocks Set to Double

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines